Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > TIME FOR AN UPDATE? A NEWSLETTER
View:
Post by ISAloser247 on Mar 06, 2012 1:11pm

TIME FOR AN UPDATE? A NEWSLETTER

..to shareholders? Since the November 01, 2011, newsletter failed to address the " the termination" with

Iljin, should not Dr. Foster give a 'clear understanding where He is going and the plans to get there."

He stated that ' we will be entering late stage development .....one of our Phase 3 trials funded by a strategic partner."   He stated that He will...........'share more information, update on future development."

IT HAS BEEN OVER A MONTH , since the

misleading shareholder letter?   FOCUS NOT ON THE SCIENCE,  BUT  THE LEGAL REMIFICATIONS OF THE SHAREHOLDER LETTER! .... someone, said, something about Napoleon,  enemies, mistakes.......

FOCUS ON THE LETTER!

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities